Cefuroxime Dosing for UTI
For uncomplicated urinary tract infections (cystitis) in adults with normal renal function, cefuroxime is NOT a first-line agent and should only be used when preferred antibiotics cannot be used, at a dose of 250 mg orally twice daily for 3-7 days, or 750 mg IV every 8 hours for 5-10 days if parenteral therapy is required.
Key Recommendation
Cefuroxime is classified as a β-lactam agent that has inferior efficacy and more adverse effects compared to other UTI antimicrobials 1. The 2011 IDSA/ESMID guidelines explicitly state that β-lactams (including cefuroxime, cefaclor, cefdinir, and cefpodoxime-proxetil) should only be used "when other recommended agents cannot be used" for uncomplicated cystitis 1.
Specific Dosing Regimens
For Uncomplicated Cystitis (Lower UTI):
Oral formulation (cefuroxime axetil):
- 250 mg twice daily for 3-7 days 1, 2
- Some studies support 125 mg twice daily for mild cases 3, 4
- Take with food to enhance absorption 3
Parenteral formulation (if IV/IM required):
- 750 mg IV/IM every 8 hours for 5-10 days 2
For Pyelonephritis (Upper UTI):
If β-lactams must be used for pyelonephritis:
- An initial IV dose of a long-acting parenteral antimicrobial (such as 1 g ceftriaxone) is recommended 1
- Continue with 750 mg to 1.5 grams IV every 8 hours 2
- Duration: 10-14 days 1
- Note: Oral β-lactams are less effective than other agents for pyelonephritis 1
Why Cefuroxime is Not First-Line
The evidence hierarchy clearly establishes preferred agents:
First-line choices for uncomplicated cystitis 1, 5, 6:
- Nitrofurantoin (100 mg twice daily for 5 days)
- Fosfomycin trometamol (3 g single dose)
- Pivmecillinam (400 mg three times daily for 3-5 days)
- Trimethoprim-sulfamethoxazole (if local resistance <20%)
First-line for pyelonephritis 1, 5:
- Fluoroquinolones (ciprofloxacin 500 mg twice daily for 7 days)
- Ceftriaxone 1 g IV (if parenteral therapy needed)
Clinical Efficacy Data
Research studies show cefuroxime axetil achieves:
- 97% clinical success rate for uncomplicated UTI 7
- 86-93% cure rates with 250 mg twice daily 4, 8
- Similar efficacy to cefotaxime for acute pyelonephritis when used parenterally 9
However, these outcomes are still inferior to first-line agents, and the guidelines emphasize using cefuroxime only when better options are unavailable 1.
Renal Dose Adjustments
Critical adjustment required for renal impairment 2:
| Creatinine Clearance | Dose | Frequency |
|---|---|---|
| >20 mL/min | 750 mg - 1.5 g | Every 8 hours |
| 10-20 mL/min | 750 mg | Every 12 hours |
| <10 mL/min | 750 mg | Every 24 hours* |
*Additional dose after hemodialysis 2
Pharmacokinetic Considerations
- Urinary concentrations: 1,150-2,500 mcg/mL after IV doses, providing excellent urinary coverage 2
- Bioavailability: 68% for oral tablets (enhanced with food) 3
- Half-life: ~80 minutes 2
- Renal excretion: 89% unchanged in urine over 8 hours 2
For UTIs specifically, even the 250 mg twice daily oral dose achieves 100% probability of target attainment for MICs up to 8 mg/L due to high urinary concentrations 10.
Common Pitfalls
- Don't use cefuroxime as empirical first-line therapy - Reserve for situations where nitrofurantoin, fosfomycin, or other preferred agents are contraindicated
- Don't forget renal dose adjustment - Cefuroxime requires significant dose reduction in renal impairment
- Don't use for pyelonephritis without initial long-acting parenteral agent - If using oral β-lactams for pyelonephritis, give ceftriaxone 1 g IV first 1
- Don't use amoxicillin or ampicillin - These have very high resistance rates and should not be used empirically 1
When Cefuroxime is Appropriate
Consider cefuroxime when:
- Patient has documented susceptibility to cefuroxime
- Allergies or contraindications to first-line agents exist
- Local resistance patterns preclude use of preferred agents
- Patient has failed first-line therapy and culture shows susceptibility